Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by equities research analysts at Goldman Sachs Group, Inc. (The) in a research report issued to clients and investors on Wednesday. They presently have a $170.00 price target on the specialty pharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s price objective would indicate a potential upside of 47.10% from the stock’s current price.
A number of other equities analysts have also recently issued reports on the stock. Mizuho restated a “neutral” rating and issued a $127.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday. Barclays PLC reaffirmed an “overweight” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday. BMO Capital Markets reaffirmed an “outperform” rating and set a $192.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, January 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $187.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, January 12th. Finally, Zacks Investment Research raised shares of Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Monday, November 14th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $179.08.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up 11.8189% during midday trading on Wednesday, reaching $129.2291. 1,770,707 shares of the company’s stock traded hands. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $160.00. The firm has a market cap of $7.74 billion, a PE ratio of 22.6004 and a beta of 1.30. The firm’s 50-day moving average is $108.39 and its 200 day moving average is $122.50.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.61 by $0.04. Jazz Pharmaceuticals PLC had a net margin of 24.81% and a return on equity of 30.50%. The firm earned $374 million during the quarter, compared to analysts’ expectations of $389.34 million. During the same quarter in the previous year, the firm posted $2.52 EPS. Jazz Pharmaceuticals PLC’s revenue was up 9.8% compared to the same quarter last year. Equities research analysts expect that Jazz Pharmaceuticals PLC will post $9.96 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2017/01/18/goldman-sachs-group-inc-the-reaffirms-buy-rating-for-jazz-pharmaceuticals-plc-jazz.html.
In related news, Director Kenneth W. O’keefe acquired 2,000 shares of the firm’s stock in a transaction dated Monday, November 14th. The stock was purchased at an average cost of $113.84 per share, with a total value of $227,680.00. Following the completion of the acquisition, the director now directly owns 12,107 shares of the company’s stock, valued at $1,378,260.88. The acquisition was disclosed in a filing with the Securities Exchange Commission, which is accessible through the SEC website. Also, Director Patrick G. Enright sold 677 shares of the business’s stock in a transaction that occurred on Friday, December 2nd. The shares were sold at an average price of $101.80, for a total transaction of $68,918.60. Following the transaction, the director now directly owns 1,365 shares of the company’s stock, valued at $138,957. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. J.Safra Asset Management Corp bought a new position in Jazz Pharmaceuticals PLC during the second quarter valued at $101,000. Tredje AP fonden bought a new position in Jazz Pharmaceuticals PLC during the second quarter valued at $102,000. Howard Hughes Medical Institute bought a new position in Jazz Pharmaceuticals PLC during the third quarter valued at $112,000. Brave Asset Management Inc boosted its position in Jazz Pharmaceuticals PLC by 540.0% in the third quarter. Brave Asset Management Inc now owns 960 shares of the specialty pharmaceutical company’s stock valued at $117,000 after buying an additional 810 shares during the last quarter. Finally, Commonwealth Bank of Australia boosted its position in Jazz Pharmaceuticals PLC by 12.6% in the second quarter. Commonwealth Bank of Australia now owns 839 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 94 shares during the last quarter. 89.21% of the stock is owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News Ratings for Jazz Pharmaceuticals PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com’s FREE daily email newsletter.